Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer
- 1 June 2002
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 36 (3) , 265-270
- https://doi.org/10.1016/s0169-5002(02)00009-0
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patientsLung Cancer, 2001
- Study of prognostic predictors for non-small cell lung cancerLung Cancer, 1999
- Revisions in the International System for Staging Lung CancerChest, 1997
- Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancerBritish Journal of Cancer, 1996
- Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung.Journal of Clinical Oncology, 1995
- Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancerThe Annals of Thoracic Surgery, 1994
- Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1British Journal of Cancer, 1994
- Clinical Significance of a Multiple Biomarker Assay in Patients with Lung CancerChest, 1990
- SERUM NEURON-SPECIFIC ENOLASE: A MARKER FOR DISEASE EXTENT AND RESPONSE TO THERAPY OF SMALL-CELL LUNG CANCERThe Lancet, 1982
- Radioimmunoassay for tumor antigen of human cervical squamous cell carcinomaCancer, 1977